Transanal Endoscopic Microsurgery for Early Rectal Cancer

Transanal endoscopic microsurgery, widely known as TEM, is a minimally invasive surgical technique that allows surgeons to remove tumors from the rectum through the anus, avoiding the need for major abdominal surgery. First introduced in 1983, it has become a standard approach for large benign rectal polyps that cannot be removed during a colonoscopy, and it plays a growing role in treating early-stage rectal cancer in carefully selected patients.¹ The procedure’s appeal lies in what it spares you: no abdominal incision, a much shorter hospital stay, and a far lower risk of needing a permanent stoma compared to traditional rectal surgery.

How TEM Works and What It Treats

During TEM, a specialized operating rectoscope (a rigid tube about 4 centimeters in diameter) is inserted through the anus and sealed to maintain a constant flow of carbon dioxide, which gently inflates the rectum and gives the surgeon a clear, magnified view of the rectal wall. The surgeon operates through this tube using long, angled instruments while watching on a high-definition screen. The key advantage over older transanal approaches is that TEM provides stable visualization and precise instrument control deep into the rectum, reaching lesions up to about 20 centimeters from the anal verge.

For benign lesions, TEM is considered the treatment of choice when a rectal adenoma is too large or positioned too awkwardly for standard colonoscopic removal.²³ Recurrence rates for benign adenomas after TEM are low, and the procedure is safe enough that it is regularly performed as a day-case or short-stay operation.⁴ Beyond adenomas, TEM has also been used for rectal fistulas, strictures, and certain carcinoid tumors, though these are less common indications.

Staging Before Surgery

If there is any suspicion that a rectal lesion might be cancerous, accurate staging is essential before deciding whether TEM alone is sufficient. The main question is how deep into the rectal wall a tumor has grown, because deeper invasion sharply increases the risk that cancer has already spread to nearby lymph nodes. TEM does not remove lymph nodes, so it is only appropriate when that risk is very low.

Endorectal ultrasound is the most common tool used to assess invasion depth before TEM. In a large series of 1,000 ultrasound exams, the overall accuracy for distinguishing non-invasive from invasive disease was about 79%, with a sensitivity of roughly 86% and a specificity around 65%.⁵ A smaller but tightly focused study reported higher overall accuracy at 92%, with no cases of understaging among patients who went on to TEM.⁶ The pattern across these studies is consistent: ultrasound is better at ruling out deep invasion than at precisely pinpointing how shallow a tumor is. Most of the errors involve overstaging, where a lesion looks deeper on ultrasound than it turns out to be under the microscope. That kind of error is relatively safe for the patient because it leads to more treatment, not less. MRI is often used alongside ultrasound, especially for lesions where cancer is suspected, to get a fuller picture of the surrounding tissue.

TEM for Early Rectal Cancer

The most debated application of TEM is in early-stage rectal cancer, specifically tumors classified as T1, meaning the cancer has grown into but not through the first layer beneath the rectal lining. The appeal is obvious: if the cancer can be completely excised through the anus, you avoid a major operation that may require removing a large segment of the rectum, creating a temporary or permanent stoma, and enduring a much longer recovery. The concern is equally obvious: TEM does not address lymph nodes, and even T1 cancers carry some risk of lymph node spread.

A meta-analysis comparing TEM with total mesorectal excision (the standard radical surgery for rectal cancer) found that for T1 cancers, there was no difference in distant spread, overall survival, or disease-free survival, but the local recurrence rate after TEM was higher.⁷ A separate meta-analysis found no statistically significant difference in local recurrence or complications between TEM and radical surgery, though this may reflect evolving patient selection.⁸ The takeaway is that TEM can produce comparable long-term results in well-selected patients, but the selection has to be rigorous.

What Makes a Cancer “Low Risk”

The histology report after TEM is the moment of truth. Several features in the removed specimen predict whether lymph nodes elsewhere might harbor cancer. The factors most consistently linked to lymph node spread are lymphovascular invasion (cancer cells in blood or lymph vessels), high-grade tumor budding (clusters of cancer cells at the advancing edge), and poor differentiation (cells that look highly abnormal under the microscope).⁹

Depth of submucosal invasion has traditionally been considered another key risk factor, but recent evidence has complicated this picture. A meta-analysis published in Gastroenterology found that when you adjust for the other features just mentioned, deep submucosal invasion on its own may not be a significant independent predictor of lymph node spread. When it was the only adverse feature, the risk of lymph node involvement was about 3%.¹⁰ Another study looking at various measurements of submucosal invasion depth, width, and area found no significant link to lymph node spread.¹¹ This is an area of active debate, and guidelines still use submucosal invasion depth as a factor, but the trend in the literature is toward giving more weight to budding, lymphovascular invasion, and differentiation grade.

Margins Matter

Clear resection margins are critical. A margin of at least 1 mm is generally considered acceptable, while margins thinner than that have been associated with recurrence rates as high as a third.¹² Very large lesions, particularly those over 30 square centimeters, are harder to remove completely. One series of giant rectal adenomas found residual adenoma tissue in about 18% of cases, with several unsuspected cancers discovered in the specimens that required further surgery.¹³

Organ Preservation After Chemoradiation

One of the more exciting recent applications of TEM is in organ-preservation strategies for rectal cancer. In this approach, patients with locally advanced rectal cancer receive chemoradiation first. Those who respond well, showing a complete or near-complete disappearance of the tumor on imaging, then undergo TEM instead of radical surgery. The idea is to confirm the response by removing the scar tissue where the tumor was, checking it under the microscope, and avoiding a permanent stoma if the pathology comes back clean.

The CARTS study followed this protocol and found that about three-quarters of patients who underwent TEM after chemoradiation were successfully treated with local excision alone. The five-year local recurrence rate was about 8%, with disease-free and overall survival rates exceeding 80%.¹⁴ A multicenter trial from China similarly concluded that TEM is a viable way to assess residual tumor in patients with a clinical complete or near-complete response, offering sphincter preservation without a significant compromise in long-term cancer outcomes.¹⁵ For patients who dread the prospect of a permanent colostomy, this approach represents a meaningful alternative, though it requires close surveillance afterward.

What Happens If the Cancer Comes Back

A central worry with any organ-sparing approach is: what if you need more surgery later? If the pathology report after TEM shows unexpected high-risk features, or if cancer recurs at the excision site, completion total mesorectal excision is the standard next step. Historically, there was concern that prior TEM would make radical surgery technically harder and compromise the specimen quality.

The evidence on this is reassuring. A study comparing completion surgery after prior TEM with primary radical surgery found no difference in local recurrence, distant metastases, or survival.¹⁶ There were more intraoperative complications in the completion group (about 18% versus 7%), but the rate of perforation at the old TEM site was not significantly different, and 30-day complication rates were comparable. When completion surgery was performed using a transanal approach, the results looked even better, with higher-quality specimens, more lymph nodes harvested, and shorter hospital stays compared to the traditional abdominal approach.¹⁷ The message here is that TEM does not burn any bridges. If radical surgery becomes necessary, it remains feasible and effective.

Close surveillance is the key to catching recurrences early enough for salvage surgery to work. One study found that long-term survival after TEM followed by timely radical salvage surgery was comparable to survival after upfront radical surgery.¹⁸ MRI can be used in the follow-up period, though postoperative scarring can confuse early scans, and its diagnostic accuracy improves over time as the surgical site matures.¹⁹ Endoscopic surveillance should be tailored to risk: in patients with a benign lesion, clear margins, and a closed defect, the yield of early follow-up endoscopy is quite low at about 1.4%, whereas higher-risk patients have a yield closer to 7%.²⁰

Complications and Recovery

TEM is generally well tolerated, but it is not complication-free. In a large series of 639 patients, the overall complication rate was about 24%, but the vast majority of those complications were minor. Clinically significant complications occurred in roughly 6% of cases, and serious outcomes were rare.²¹ Rectal bleeding was the most common issue, accounting for most of the overall complication number, but about four out of five bleeding episodes were minor and self-limiting. The highest-risk period was the first two days after surgery.

Three factors stood out as increasing complication risk: tumor size greater than 6 centimeters, the use of antiplatelet medication, and having a surgeon with fewer than 150 TEM procedures under their belt.²² Entry into the peritoneal cavity is an uncommon but recognized risk, particularly for tumors on the front or side wall of the rectum. In most cases, this can be managed without converting to an abdominal operation.²³

One common concern is whether the large rectoscope damages the anal sphincter. Studies using validated continence questionnaires have found that quality of life related to fecal incontinence actually improved after TEM, and continence itself was not worsened by the procedure.²⁴ Satisfaction with continence was generally high, though full-thickness excision and the removal of malignant rather than benign lesions were associated with somewhat more continence issues.²⁵ Compared to radical rectal surgery, these functional effects are minor.

Alternatives to TEM

TEM is not the only way to remove rectal lesions without major surgery. Two alternatives deserve attention: transanal minimally invasive surgery (TAMIS) and endoscopic submucosal dissection (ESD).

TAMIS

TAMIS uses a flexible single-port access device inserted through the anus instead of the rigid TEM rectoscope, and the surgeon operates with standard laparoscopic instruments. This makes it cheaper to set up and arguably easier to learn, since most colorectal surgeons already have laparoscopic skills. Comparative studies show that TEM and TAMIS produce equivalent results in terms of excision quality and complication rates, with TAMIS having the edge in shorter operating times.²⁶ Current clinical data treat them as effectively equivalent platforms.²⁷ TAMIS has been gaining popularity, particularly in settings where the dedicated TEM equipment is not available.

Endoscopic Submucosal Dissection

ESD is a purely endoscopic technique, performed through a flexible endoscope rather than through a surgical platform. It involves injecting fluid beneath the lesion to lift it away from the deeper layers and then carefully dissecting it off. How ESD stacks up against TEM depends on which studies you read and from which era. An earlier meta-analysis found that TEM achieved higher en bloc and complete resection rates than ESD, while ESD had a lower recurrence rate, possibly because it captures the lesion in one piece more cleanly when successful.²⁸ A more recent meta-analysis found the opposite pattern, favoring ESD for en bloc rates, recurrence, and overall complications.²⁹ Meanwhile, a randomized controlled trial found that TEM achieved significantly higher complete (R0) and en bloc resection rates, while recurrence at two years was essentially the same between the two approaches.³⁰

The practical difference often comes down to full-thickness versus mucosal excision. TEM can remove the full thickness of the rectal wall, which is essential when cancer staging depends on knowing exactly how deep a tumor has grown. ESD is limited to the mucosal and submucosal layers. For flat benign polyps without any suspicion of invasive cancer, ESD performed by an experienced endoscopist may be a reasonable first option, especially since it avoids anesthesia-related risks and may be less costly. But for anything where cancer depth matters, TEM’s ability to provide a full-thickness specimen gives it a structural advantage.

The Learning Curve

TEM is technically demanding, and this is one of the main reasons it has not been adopted more widely despite decades of availability. The rectoscope creates a long, narrow working channel, and the instruments pivot in unfamiliar ways compared to standard laparoscopic surgery. Studies of the learning curve have found that it significantly affects conversion rates, procedure duration, and complication rates, though not recurrence rates.³¹ One large series identified experience below 150 procedures as a risk factor for complications, as noted earlier.

Simulation-based training programs have been developed to shorten this curve. A step-by-step program using cadaveric and simulator models has shown it can help trainees build the core skills needed regardless of their prior surgical experience.³² For TAMIS, simulator studies suggest trainees need somewhere around 15 to 20 sessions to reach a stable level of competence.³³ The steep learning curve is one reason why expert recommendations call for centralizing TEM at high-volume centers where surgeons can maintain proficiency.

Cost Considerations

The economic case for TEM over radical surgery is straightforward when it is the definitive procedure. One cost analysis found that TEM was roughly a seventh the cost of open rectal resection, with massive cumulative savings across a surgical series, and the initial capital cost of the TEM equipment (about £40,000 at the time) was recovered quickly.³⁴ Shorter hospital stays and fewer complications drive most of the savings.

The comparison with endoscopic alternatives is less flattering. A cost-effectiveness analysis of complex benign rectal polyps found that endoscopic resection had substantially lower lifetime costs than either TEM or TAMIS, despite TEM producing a marginally better quality-adjusted life outcome.³⁵ For purely benign polyps that an experienced endoscopist can handle, endoscopic removal first often makes more sense economically. TEM’s value proposition is strongest when the lesion is too large or awkwardly placed for endoscopy, or when full-thickness excision is needed for cancer staging.

What Patients and Surgeons Weigh Differently

One of the more striking findings in this field is how differently patients and their surgeons think about risk trade-offs. When researchers asked both groups about nonoperative or organ-sparing approaches versus radical surgery for low rectal cancer, patients were willing to accept much larger trade-offs to avoid a permanent colostomy. Patients would tolerate a 20% increase in local regrowth risk and a 20% decrease in overall survival to avoid abdominoperineal resection, whereas physicians would only accept a 5% increase in recurrence and a 5% decrease in survival.³⁶ This gap matters because it suggests that shared decision-making conversations need to explicitly address how much weight the patient places on avoiding a stoma versus minimizing recurrence risk. TEM and organ-preservation protocols sit squarely in that gap: they offer a middle path that eliminates neither the cancer risk entirely nor the quality-of-life burden entirely, and the right choice depends heavily on individual values.